5 Key Questions 2018-09-17T15:59:48+00:00

Why Choose Neo Matrix Medical?

At Neo Matrix Medical, we are a few steps ahead of the competition. Below are the 5 Key Questions you should ask before you decide on Stem Cell Therapy…You will be glad you did.

Contact Us

Upcoming Seminars

Thursday, September 20th
2 PM
Saturday, September 22nd
1 PM
Saturday, October 6th
1 PM
Tuesday, October 9th
1 PM
Thursday, October 11th
1 PM
Tuesday, October 16th
1 PM
Tuesday, October 16th
7 PM
Thursday, October 18th
1 PM
Sunday, October 21nd
1 PM

(833) 242-5544

5 KEY QUESTIONS TO ASK WHEN CONSIDERING

STEM CELL THERAPY

  1. WHAT IS THE SOURCE OF THE STEM CELLS?
  2. HOW MANY LIVE MESYNCHYMAL STEM CELLS DOES THE END PRODUCT CONTAIN PER 1ML OR 1CC?
  3. IS THE PRODUCT IN FULL COMPLIANCE WITH SECTION 361 HCT/P (Human Cellular Tissues / Products) of the FDA?
  4. HOW DO YOU INJECT THE PRODUCT? WHAT TYPE OF IMAGING DO YOU USE TO DELIVER THE PRODUCT ACCURATELY TO THE DAMAGED AREAS?
  5. HOW MANY PROCEDURES HAS YOUR COMPANY PERFORMED THUS FAR, AND WHAT IS YOUR SUCCESS RATE?

Download  PDF Version Here

QUESTION 1: WHAT IS THE SOURCE OF THE STEM CELLS?

Stem cells can be obtained from various sources. Not all sources of stem cells are equal in their capability to repair and re-engineer soft tissue, connective tissue or nerve tissue.

  • The use of embryonic stem cells is illegal. In addition to the moral and ethical issues that exist when harvesting stem cells from aborted fetal tissue, embryonic stem cells have been shown to cause teratomas (tumors) in mice. Embryonic stem cells are only used in research and will NEVER be used in the therapeutic applications for humans.
  • Adults stem cells (derived from bone marrow or adipose tissue of the patient) have many disadvantages compared to MSC (mesynchymal stem cells) derived from the umbilical cord matrix (Wharton’s Jelly).

RESEARCH clearly shows the benefits of Umbilical Cord/Wharton’s Jelly  MSC (mesynchymal stem cells) versus MSC from Bone Marrow or Adipose Tissue:

The number of stem cells in our body significantly declines with age:

“Young” stem cells (MSC from the umbilical cord matrix):

  • Are obtained from non-invasive procedures unlike liposuction or bone marrow collection, which increase risk, cost and liability.
  • Have a far greater ‘fitness’ level and therefore are able to replicate at greater and faster rates.
  • Have a much greater and faster healing response.
  • Have a higher proliferative capacity.
  • Have a stronger inflammatory protective effect and a strong migratory ability toward the site of inflammation.
  • Have a larger amount of different growth factors, especially bFGF 20.
  • Have the ability to differentiate into adipogenic, osteogenic, chondrogenic, neural cells and Schwann cells; and help organize tendon collagen fibers and induce hepatocyte differentiation.
  • Have been shown to differentiate into nervous system cells, liver, pancreas, heart, and other organs of the body.
  • Are more robust. The range and level of specific cytokines is greater than those expressed by adult MSC.
  • Sustain less damage from reactive oxygen species (ROS).
  • Retain telomere at the highest possible length which protects them from premature loss of viability.
  • Continue to express molecules with immune-modulating activity after they are extracted from the umbilical cord and able to pass this ability to their progeny. This enables the infused donor cells, whether differentiated or not, to engraft into the diseased target organ and positively modify its microenvironment to promote re-population. The infusion of immunomodulatory MSC provide a significant advantage by better overcoming host responses, providing the needed functional bridging action, and modifying the underlying pathological conditions at the basis of disease.
  • Provoke little to no immune response when transplanted; cell rejection is not an issue and human leukocyte antigen (HLA) matching is not necessary (as with adult stem cells).
  • Have Immunomodulatory properties: they do not pose risk for metastasis of tumor cells and in fact promote proteins that halt the cell cycle of cancer cells and promote tumor suppressing genes.

All the above research facts (references listed below) are easily illustrated in the following real-life example:

When a young child falls and cuts him/herself, how long does that cut or wound take to heal? 24-48 hours, right? What if you fall and cut yourself? Indeed, several weeks or even longer. That’s because the healing properties of the young child are at its peak. The young MSC (mesynchymal stem cells) have a far greater and faster healing capacity than our aged body stem cells.

Besides the significantly reduced QUANTITY and QUALITY of adult derived MSC, the other essential components for effective tissue repair and tissue engineering are missing with adult stem cell therapies. These other essential components include growth factors, cytokines, HA (hyaluronic acid), and several other bio-active molecules.

CONCLUSION:

THE YOUNGER THE STEM CELLS,

THE MORE POWERFUL THE STEM CELLS.

Stem cells from the newborn are much higher in quantity and have the ability to replicate much faster. Therefore, young stem cells heal, repair, modulate and renew soft tissue much better and much faster.

QUESTION 2: DO YOU KNOW HOW MANY MSCs & OTHER REGENERATIVE FACTORS ARE IN THE END PRODUCT PER CC?

Most companies or manufacturers do not have the financial resources to have their products tested by a Third Party, or they wish not to have them tested since the test results may be disappointing.

Regardless, as a consumer you must ask the exact amount of live MSC (mesynchymal stem cells) that the end-product (the product you will be injected with) contains for each 1cc or 1ml. Why? A product that lacks live MSC’s or does not contain live cells will NOT produce the result you are looking for.

The average viable (live) MSC (mesynchymal stem cells) that are in our product ranges from 1.0 Million to 1.2 Million per 1 cc.

CONCLUSION:

OUR PRODUCT CONTAINS 1-1.2 MILLION LIVE MSC’S/CC.

QUESTION 3: IS THE PRODUCT IN FULL COMPLIANCE WITH THE FDA GUIDELINES UNDER SECTION 361 HCT/P (Human Cellular Tissues / Products)?

WHERE does umbilical cord tissue come from?

All birth tissue products are obtained from C-section deliveries from normal, full-term pregnancies in U.S. Donors that consent to use of their birth tissues are carefully screened prior to the use of their tissues in manufacturing our products.

Comprehensive medical and social histories of the donors are obtained and tissues are procured, processed, and tested in accordance with standards established by the AATB (American Association of Tissue Banks) and FDA requirements to minimize potential risks of disease transmission to recipients. Infectious disease testing is performed at a certified laboratory in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493.

Each donor is tested for HBsAg (Hepatitis B Surface Antigen), HBcAb (hepatitis B core Antibody), HCV (hepatitis C Antibody), HIV I/II-Ab (Antibody to Human Immunodeficiency Virus Types 1 and Syphilis detection test, HIV NAT (HIV Nucleic Acid Test), and HCV NAT (HCV Nucleic Acid Test).

All products are tested post-sterilization to demonstrate the absence of bacterial and fungal pathogens and are non-pyrogenic. All testing results are reviewed by the Medical Director of Predictive Biotech (2749 E. Parleys Way, Suite 101, Salt Lake City, UT 84109) prior to the release of the product.

The FDA identified “Umbilical Cord Tissue” as a “structural tissue” and states that structural tissue, in addition to cytokines and other factors, can and may have live cells present. The products we use align directly with the FDA “Homologous Use” definition for structural tissues. The product we use is fully compliant with all Section 361 regulations of the FDA.

QUESTION 4: HOW DO YOU INJECT THE PRODUCT? WHAT TYPE OF IMAGING DO YOU USE TO DELIVER THE PRODUCT ACCURATELY TO THE DAMAGED AREAS?

Unlike many practitioners who perform ‘blind’ injections and don’t use an imaging modality to accurately identify the damaged areas and place the product accordingly, at Neo Matrix Medical we use a 100% safe imaging modality to optimize our results.

As part of your examination prior to your musculoskeletal or joint injection, a diagnostic musculoskeletal (MSK) ultrasound is performed to determine the current state of the injured area and to identify the specific location of the injury. The ultrasound exam provides real-time imaging that can evaluate the health/injury of tendons, muscle, ligaments, bone, cartilage, and bursa.

The exam consists of an ultrasound specialist using a water-based gel, as a coupling agent, and an ultrasound probe for imaging the internal structures. The sonographer will place the probe over the injured area to assess for any damage to the musculoskeletal tissue. A specific protocol will be followed for your area of concern. Based on the amount of damage and the locations of the injuries, a detailed plan of action will be designed specifically to fit your needs. After sterilizing the treatment area and using a local anesthetic to provide comfort, the MSK ultrasound is used for the delivery of product to the specific site/sites of trauma.

The use of high-quality musculoskeletal ultrasonography is considered a key part of the process, particularly considering that this modality plays a central role for clinicians to effectively hit the desired targets. Optimal placement correlates with earlier and improved outcomes, making it an essential component of our regenerative therapy applications at Neo Matrix Medical.

CONCLUSION:

THE USE OF SAFE MSK (MUSCULOSKELETAL) ULTRASOUND ALLOWS FOR THE ACCURATE PLACEMENT OF THE PRODUCT IN THE DAMAGED OR INJURED AREAS.

QUESTION 5: HOW MANY PROCEDURES HAS YOUR COMPANY PERFORMED THUS FAR, AND WHAT IS YOUR SUCCESS RATE?

Neo Matrix Medical & Vitality Health Care have performed tens of thousands of procedures in their clinics across the country over the past 4+ years. At Neo Matrix Medical we specialize in Stem Cell Therapy and stem cell therapy is the only service we offer. We treat patients with conditions that recent literature and published research, along with our vast experience show to be responding very well to our pure Wharton’s Jelly MSC’s. These conditions include neuropathies, a multitude of orthopedic conditions and auto-immune disorders.

There are no guarantees in medicine, period. However, our current success rate across our clinics nationwide is 94.4%. That is an extremely high success rate which we contribute to our highly professional approach.

CONCLUSION:

WE HAVE PERFORMED TENS OF THOUSANDS OF PROCEDURES AND HAVE A SUCCESS RATE OF 94.4%

SUMMARY

When researching stem cells or when considering stem cell therapy, one has to be careful with his/her selection since not all stem cells are equal and not all providers are compliant with current FDA regulations.

At Neo Matrix Medical / Vitaly HealthCare, we have the most viable source of stem cells available to effectively treat our patients. Adult stem cell therapies (stem cells obtained from the aging body) have many disadvantages and the results obtained are far inferior and inconsistent. Stem cells from the Wharton’s Jelly of the umbilical cord of the newborn are high in quantity and quality. They can replicate at much higher rates and therefore heal, repair, modulate and renew soft tissue much better and much faster.

Make sure that when you compare stem cell sources and products, you consider the advantages and disadvantages, and verify the amount of live MSC/cc of the end-product. Most providers or manufacturers can NOT verify the amount of live MSC’s in their product.

For better and faster results, MSK Ultrasound imaging is used to safely diagnose and accurately place the product in the injured areas. Unlike with so-called “blind” injections (absence of an imaging modality), accurate placement allows for optimal results.

At Neo Matrix Medical / Vitaly HealthCare, we have performed tens of thousands of stem cell therapy procedures nationwide over the past 4+ years and we are very proud of our 94.4% success rate.

It’s time to do what thousands of people have already done – successfully – and that is to take back your life with Vitality Stem Cell Therapy!

 Published Studies for the Efficacy of Allograft Tissue Products Derived from Birth Tissue (Wharton’s Jelly)

  1. Human Umbilical Cord-Derived Mesenchymal Stem Cells Do Not Undergo Malignant Transformation during Long-Term Culturing in Serum-Free Medium

 2. Batsali, A. Comparative Analysis of Bone Marrow and Wharton’s Jelly Mesenchymal Stem/Stromal Cells. Blood.
2013:122:1212.

 3. Batsali, AK et.al. Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and
emerging clinical applications. Current Stem Cell Research and Therapeutics. 2-13 Mar: 8(2): 144-55.

 4. DiMarino, A. et.al. Mesenchymal Stem Cells in Tissue Repair. Frontiers in Immunology. 2013;4:201.

 5. Doi, H. et.al. Potency of umbilical cord blood- and Wharton’s jelly-derived mesenchymal stem cells for scarless wound
healing Scientific Reports 6 :18844(2016).

 6. F Gao et.al. Mesenchymal stem cells and immunomodulation: current status and future prospects Cell Death and
Disease (2016) 7, e2062; doi:10.1038/cddis.2015.327.

 7. Hye, J. et.al. Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and
Umbilical Cord Blood as Sources of Cell Therapy. International Journal of Molecular Science 2013 Sep: 14(9):
17986-18001.

 8. Hsieh J-Y, Wang H-W, Chang S-J, Liao K-H, Lee I-H, Lin W-S, et al. (2013) Mesenchymal Stem Cells from Human
Umbilical Cord Express Preferentially Secreted Factors Related to Neuroprotection, Neurogenesis, and Angiogenesis.
PLoS ONE 8(8): e72604. doi:10.1371/journal.pone.007260

 9. Kalaszczynska, I and Ferdyn, K. Wharton’s Jelly Derived Mesenchymal Stem Cells: Future of Regenerative Medicine?
BioMed Research International. Vol 2015 article ID 430847.

 10. Liu, Y. et.al. Therapeutic Potential of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Rheumatoid
Arthritis. Arthritis Research and Therapeutics. 2010; 12(6): R 210.

 11. Murphy, M. et.al. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine.
Experimental and Molecular Medicine. 2013 Nov; 48(1) e54.

 12. Sobolewski, K. et.al. Wharton’s jelly as a reservoir of peptide growth factors. Placenta. 2005 Nov;26(10):747-52.

 13. Watson, N. et.al. Discarded Wharton’s Jelly of the Human Umbilical Cord: A Viable Source for Mesenchymal Stem
Cells. Cytotherapy. 2015 January; 17(1): 18-24.

 14. Ye, B. et.al. Rapid biomimetic mineralization of collagen fibrils and combining with human umbilical cord mesenchymal
stem cells for bone defects healing. Material Science and Engineering C Material Biology Appl. 2016 Nov 1, 68:
43-51.

 15. Bellamy, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev.
2006 Apr 19;(2):CD005321

 16. Didier Demesmin, MD Amniotic Fluid as a Homologue to Synovial Fluid: Interim Analysis of Prospective, Multi-Center
Outcome Observational Cohort Registry of Amniotic Fluid Treatment for Osteoarthritis of the Knee Presented at the
2015 AAPM Annual Meeting

 17. Brohlin, et. al, Characterisation of human mesenchymal stem cells following differentiation into Schwann cell-like
cells. Neuroscience Research. 2009, 64(1):41-49.

 18. Chaudhury, S. Mesenchymal stem cell applications to tendon healing. Muscles Ligaments Tendons J. 2012 Jul-Sep;
2(3): 222–229.

 19. Udalamaththa, V. et.al. Potential Role of Herbal Remedies in Stem Cell Therapy: Proliferation and Differentiation of
Human Mesenchymal Stromal Cells Stem Cell Research and Therapy. (2016) 7:110.

 20. Aleynik , et. al. Stem cell delivery of therapies for brain disorders. Clinical and Translational Medicine 2014, 3:24

 21. Li, et. al, Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under
xeno-free conditions for cell therapy. Stem Cell Res Ther. 2015; 6(1): 55.

 22. Anzalone R, et al. Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the
differentiation and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.
Stem Cell Rev. 2011; 7(2):342-63.

 23. Tesche LJ, Gerber DA. Tissue-derived stem and progenitor cells. Stem cells international. 2010; 2010:824876.

 24. Kalaszczynska, et. al, Wharton’s Jelly Derived Mesenchymal Stem Cells: Future of Regenerative Medicine? Recent
Findings and Clinical Significance. Biomed Res Int. 2015; 2015: 430847

RSVP for one of our FREE Seminars

Learn all about stem cells and stem cell therapy, and find out if stem cell therapy may benefit YOU!

FREE 1-hour seminars

First Name
Last Name
Phone Number
Email Address
Seminar Date & Time
How did you find us?